Single-Agent Taxanes in Advanced Breast Cancer: A Commentary

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 7 No 2
Volume 7
Issue 2

Taxanes have been established in the treatment of metastatic breast cancer, and two presentations at the 20th Annual San Antonio Breast Cancer Symposium provide additional data to more clearly delineate the indications and potential use of these agents.

Taxanes have been established in the treatment of metastatic breast cancer, and two presentations at the 20th Annual San Antonio Breast Cancer Symposium provide additional data to more clearly delineate the indications and potential use of these agents.

Dr. John Crown (see page 2) reported the results of the TAX-303 trial comparing docetaxel (Taxotere) at 100 mg/m2 with doxorubicin at 75 mg/m2. The overall response rate for docetaxel was 48%, versus 33% for doxorubicin in 300 randomized patients, demonstrating a statistically significant higher response rate. Responses appeared to be more rapid for the docetaxel-treated patients. There was no difference in time to progression.

The docetaxel response rate was similar to that reported in previous phase II studies: the doxorubicin rate was similar to that in other randomized trials.

Most patients had previous alkylator therapy, but no patients had prior taxane or anthracycline treatment, and half the patients were chemotherapy-resistant. The toxicity profile was more favorable for docetaxel versus doxorubicin.

Another exciting study was presented by Dr. Hans-Joachim Luck (see page 3) evaluating the role of weekly paclitaxel (Taxol) in heavily pretreated metastatic breast cancer patients. He reported that 15 of 41 patients had a partial response; 30% of the patients had received prior taxane-based therapy and 10 had received both an anthracycline and a taxane. Not only did he find a significant response rate, but this regimen was well tolerated without severe neutropenia.

Dr. Luck’s findings confirm reports of high activity for weekly paclitaxel in heavily pretreated patients presented at ASCO 1997. These results likely reflect overall time of cellular exposure to a drug with schedule-dependent pharmacokinetics. This offers a tolerable, palliative approach to the management of heavily pretreated advanced breast cancer patients.

These reports of single-agent taxane use show that they are extremely active, and future clinical trials with these agents in combination therapy and in the adjuvant setting are currently ongoing.

Related Videos
Sara M. Tolaney, MD, MPH, an expert on breast cancer
Sara M. Tolaney, MD, MPH, an expert on breast cancer
The August CancerNetwork Snap Recap takes a look back at key FDA news updates, as well as expert perspectives on the chemotherapy shortage.
Ann H. Partridge, MD, MPH, talks about how fertility preservation can positively impact the psychosocial health in patients with breast cancer.
Daniel G. Stover, MD, describes how findings from the phase 3 NATALEE trial may support expanding the portion of patients who receive CDK 4/6 inhibitors as a treatment for hormone receptor–positive, HER2-negative breast cancer.
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Sara M. Tolaney, MD, MPH, discusses how, compared with antibody-drug conjugates, chemotherapy produces low response rates and disease control in the treatment of those with hormone receptor–positive, HER2-negative metastatic breast cancer.
Hope Rugo, MD, speaks to the importance of identifying patients with aromatase inhibitor–resistant, hormone receptor–positive, HER2-negative advanced breast cancer who are undergoing treatment with capivasertib/fulvestrant who may be at a high risk of developing diabetes or hyperglycemia.
Sara M. Tolaney, MD, MPH, describes the benefit of sacituzumab govitecan for patients with HER2-low metastatic breast cancer seen in the final overall survival analysis of the phase 3 TROPiCS-02 study.
An expert from Dana-Farber Cancer Institute describes which patients hormone receptor-positive,  HER2-negative breast cancer will benefit most from treatment with sacituzumab govitecan.
Related Content